Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
Abstract This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of...
Main Authors: | Hugo Marcel Vanderstichele, Charlotte E. Teunissen, Eugeen Vanmechelen |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-12-01
|
Series: | Neurology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40120-019-00166-3 |
Similar Items
-
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-06-01) -
Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy
by: Yingjian You, et al.
Published: (2019-02-01) -
Advances and considerations in AD tau-targeted immunotherapy
by: Alice Bittar, et al.
Published: (2020-02-01) -
Inhibiteurs et modèles moléculaires de fibres amyloïdes ° et tau impliquées dans la maladie d'Alzheimer : conception, synthèse et caractérisation
by: Dufour, Emilie
Published: (2013) -
Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers
by: Ting-Bin Chen, et al.
Published: (2021-10-01)